Arthur Przybyl Sells 9,595 Shares of ANI Pharmaceuticals Inc (ANIP) Stock

ANI Pharmaceuticals Inc (NASDAQ:ANIP) CEO Arthur Przybyl sold 9,595 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $71.10, for a total transaction of $682,204.50. Following the transaction, the chief executive officer now owns 222,994 shares of the company’s stock, valued at approximately $15,854,873.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Arthur Przybyl also recently made the following trade(s):

  • On Wednesday, May 15th, Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.07, for a total transaction of $2,102,100.00.
  • On Tuesday, March 19th, Arthur Przybyl sold 27,625 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.53, for a total transaction of $1,755,016.25.

Shares of ANIP traded up $1.91 during trading hours on Thursday, reaching $71.05. The company had a trading volume of 3,420 shares, compared to its average volume of 87,476. The company has a quick ratio of 0.67, a current ratio of 0.92 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $836.09 million, a PE ratio of 15.39 and a beta of 2.37. ANI Pharmaceuticals Inc has a 12-month low of $36.92 and a 12-month high of $74.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.25. The business had revenue of $52.90 million during the quarter, compared to the consensus estimate of $50.57 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The business’s revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.32 EPS. On average, research analysts anticipate that ANI Pharmaceuticals Inc will post 5.97 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in ANIP. First Trust Advisors LP grew its stake in ANI Pharmaceuticals by 1.2% in the 1st quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock valued at $1,067,000 after acquiring an additional 179 shares during the last quarter. Texas Permanent School Fund boosted its stake in shares of ANI Pharmaceuticals by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 5,633 shares of the specialty pharmaceutical company’s stock worth $397,000 after purchasing an additional 206 shares during the last quarter. Comerica Bank boosted its stake in shares of ANI Pharmaceuticals by 3.1% during the 1st quarter. Comerica Bank now owns 8,239 shares of the specialty pharmaceutical company’s stock worth $570,000 after purchasing an additional 248 shares during the last quarter. THB Asset Management boosted its stake in shares of ANI Pharmaceuticals by 1.1% during the 1st quarter. THB Asset Management now owns 25,431 shares of the specialty pharmaceutical company’s stock worth $1,793,000 after purchasing an additional 275 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of ANI Pharmaceuticals by 3.2% during the 1st quarter. Swiss National Bank now owns 16,200 shares of the specialty pharmaceutical company’s stock worth $1,143,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 60.02% of the company’s stock.

ANIP has been the subject of a number of research analyst reports. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Raymond James set a $73.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Finally, Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price target for the company in a report on Thursday, March 28th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. ANI Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $84.25.

ILLEGAL ACTIVITY NOTICE: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://transcriptdaily.com/2019/05/16/arthur-przybyl-sells-9595-shares-of-ani-pharmaceuticals-inc-anip-stock.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: What are the benefits of a balanced fund?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.